Form 4 for MDGL MADRIGAL PHARMACEUTICALS, INC.
Accepted 2023-12-11 00:00:00 ET · period of report 2023-12-07 · accession 0000899243-23-020582 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| MI | 2023-12-11 | 2023-12-07 | MDGL | CRAVES FRED B | Dir | J - Other | $0.00 | -1.56M | 0 | -100% | $0 |
| I | 2023-12-11 | 2023-01-30 | MDGL | CRAVES FRED B | Dir | G - Gift | $0.00 | -3,557 | 57.1K | -6% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-12-07 | J | D | 46,073 | $0.00 | 1,261 | I See Footnotes | — | — | (F7) Includes 46,073 shares of Common Stock previously reported as indirectly held by Fund IV. (F1) Bay City Capital LLC, a Delaware limited liability company ("BCC"), Bay City Capital Management IV LLC, a Delaware limited liability company ("Management IV"), and Bay City Capital Fund IV, L.P., a Delaware limited partnership ("Fund IV"), are deemed to be a "group" for the purposes of Section 13(d) under the Securities Exchange Act of 1934. Management IV is the general partner of Fund IV and has sole voting and dispositive power with respect to the securities held by Fund IV. BCC, the manager of Management IV, is also an advisor to Fund IV and has sole voting and dispositive power with respect to the securities held by Fund IV. (F3) These securities are held by BCC. Dr. Craves disclaims beneficial ownership of these securities held by BCC, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such shares, except to the extent of his pecuniary interest, if any, in the securities by virtue of the limited liability company interests he owns in BCC. |
| 2 | Common | Common Stock | 2023-01-30 | G | D | 3,557 | $0.00 | 57,062 | I See Footnote | — | — | (F4) Represents shares held indirectly by Dr. Craves through a grantor retained annuity trust and reflects the transfer of 29,381 shares of Common Stock to the reporting person from the grantor retained annuity trust. |
| 3 | Common | Common Stock | 2023-12-07 | J | D | 1,510,521 | $0.00 | 0 | I See Footnotes | — | — | (F2) These securities were held by Fund IV. Dr. Craves disclaims beneficial ownership of these securities previously held by Fund IV, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such shares, except to the extent of his pecuniary interest, if any, in the securities by virtue of the limited liability company interests he owns in BCC. (F1) Bay City Capital LLC, a Delaware limited liability company ("BCC"), Bay City Capital Management IV LLC, a Delaware limited liability company ("Management IV"), and Bay City Capital Fund IV, L.P., a Delaware limited partnership ("Fund IV"), are deemed to be a "group" for the purposes of Section 13(d) under the Securities Exchange Act of 1934. Management IV is the general partner of Fund IV and has sole voting and dispositive power with respect to the securities held by Fund IV. BCC, the manager of Management IV, is also an advisor to Fund IV and has sole voting and dispositive power with respect to the securities held by Fund IV. |